IDXX vs NEOG
Idexx Laboratories Inc. and Neogen Corp., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | IDXX | NEOG |
|---|---|---|
| Revenue | $4.3B | $870.4M |
| Net income | $1.1B | $-7.9M |
| Gross margin | 61.8% | 46.9% |
| Net margin | 24.6% | −0.9% |
| Return on equity | 66.2% | −0.4% |
| Diluted EPS | $13.08 | −$0.04 |
| Dividend / share | — | — |
| Payout ratio | — | — |
| Free cash flow | $1.1B | $31.9M |
| Equity | $1.6B | $2.1B |
| Net debt / equity | 0.17× | 0.29× |
| Current ratio | 1.23× | 3.82× |
| Revenue CAGR 5y | 9.7% | 13.2% |
| Profit CAGR 5y | 12.7% | — |
IDXX bills 4.9× the revenue of NEOG, and NEOG closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Revenue by year
10 years side by side
| Fiscal year | IDXX | NEOG |
|---|---|---|
| FY2025 | $4.3B | $870.4M |
| FY2024 | $3.9B | $894.7M |
| FY2023 | $3.7B | $924.2M |
| FY2022 | $3.4B | $822.4M |
| FY2021 | $3.2B | $527.2M |
| FY2020 | $2.7B | $468.5M |
| FY2019 | $2.4B | $418.2M |
| FY2018 | $2.2B | $414.2M |
| FY2017 | $2.0B | $397.9M |
| FY2016 | $1.8B | $358.3M |
Net income by year
Bottom line
| Fiscal year | IDXX | NEOG |
|---|---|---|
| FY2025 | $1.1B | $-7.9M |
| FY2024 | $887.9M | $-1.1B |
| FY2023 | $845.0M | $-9.4M |
| FY2022 | $679.1M | $-22.9M |
| FY2021 | $744.8M | $48.3M |
| FY2020 | $581.8M | $60.9M |
| FY2019 | $427.7M | $59.5M |
| FY2018 | $377.0M | $60.2M |
| FY2017 | $263.1M | $63.1M |
| FY2016 | $222.0M | $43.8M |
More in this industry